• Forest Laboratories Inc., of New York, reported top-line results from two Phase III trials of cariprazine (RGH-188) in acute exacerbation of schizophrenia, showing that patients treated with the dopamine D3-preferring D3/D2 receptor partial agonist experienced significant symptom improvement compared to the placebo group, as measured by the Positive And Negative Syndrome Scale, the primary endpoint in both studies.